

**Debra Schwab Brandt, D.O.**

Northwestern Connecticut Oncology/Hematology Associates, LLP

19 West Main Street  
Sharon, CT 06069

**200 Kennedy Drive  
Torrington, CT 06790**

New Milford Cancer Center  
21 Elm St, New Milford, CT 06776

Phone (860) 482-5384  
Fax (860) 489-1799  
Home phone (860) 567-8927

---

**Specialties** - Medical Hematology and Medical Oncology and Internal Medicine

1998 - present      Private Practice- Northwest Connecticut Oncology/Hematology  
Associates

1998 – present      Director of Clinical Trials - Responsible for Overseeing Clinical  
Trials

**Hospital Privledges** - Charlotte Hungerford Hospital, New Milford Hospital,  
Sharon Hospital

**Postdoctoral Training**

Fellowship: Yale University- New Haven, Connecticut  
7/95 - 6/98      Hematology/Oncology Department

Residency: UMDNU-Robert Wood Johnson University Hospital-New Brunswick, N.J/  
7/93 - 6/95      Internal Medicine Department

Residency: Beth Israel Medical Center-New York, N.Y.  
7/92 - 6/93      Internal Medicine Department

Internship: Union Hospital-Rotating Internship-Union, N.J.  
7/91-6/91

**Education**

Medical: Des Moines University- Des Moines, Iowa  
7/87 - 6/91      Degree: D.O.

College: Brandeis University- Waltham, MA 02154  
8/83 – 6/87      Degree: B.A.

Licensure: Connecticut: current

Board Certification: Osteopathic National Boards 1991  
Internal Medicine 1995  
Medical Oncology 1998  
Medical Hematology 1999

## **Debra Schwab Brandt, D.O.**

Northwestern Connecticut Oncology/Hematology Associates, LLP

---

### **Honors and Awards**

Sigma Sigma Phi - National Honor and Service Society.

Ram's Head Award - Expertise in Osteopathic manipulation

*Connecticut Magazine*: Best Doctor in Connecticut Award as Chosen by Peers 2004

### **Research**

- 1) Research Director at NW Oncology/Hematology Associates. Participate in ECOG, Yale Oncology Network, and pharmaceutical company driven protocols.
- 2) Laboratory Experience: One year exploring the biochemical mechanism for synergistic activity between fludarabine and cyclophosphamide (with Dr. Ed Chu-Yale University).
- 3) Clinical Protocol Investigator: Phase II trial of cytoxan, vincristine, and fludarabine in patients with CLL and primary and refractory low grade non-hodgkin's lymphoma.

### **Publications**

- 1) Salloum, E., Brandt, D., Caride E., et al.: Gallium Scans in the Management of Patients with Hodgkin's Disease: A Study of 101 Patients: JCO 15, 518-527, 1997.
- 2) Brandt, D. and Chu, E.: Future Challenges in the Clinical Development of Thymidylate Synthase Inhibitor Compounds, Onc. Res. 9: 403-410, 1998.
- 3) Brandt, D. and Chu, E.: The development of the TS Inhibitor Compounds in the treatment of human colorectal cancer., Advances in Colon Cancer, 10, 1997.
- 4) Brandt, D. and Chu, E.: Rescue agents for 5-fluorouracil., Advances in Colon Cancer, publication pending.
- 5) Fischer, D.S., Knobf, T.M. and Durivage, H.J.: The Cancer Chemotherapy Handbook, Mosby Yearbook Inc. 1997. Aided in the research and writing of the chapter on combination chemotherapy.

### **Appointments**

2002-present: Transfusion Committee-chair

1999-present: Institutional Review Board

1999-present: Pharmacy and Therapeutics Committee

1998-present: Cancer Committee

2000-present: Programming Committee

### **Memberships**

ASCO, AMA, AOA, ASH, Connecticut Oncology Associates, ECOG, Yale Oncology Network